Alterations in the Antimicrobial Resistance Profile of Acinetobacter baumannii Strains Isolated from Intensive Care Unit Patients: Five-Year Follow-up in Cappadocia
DOI:
https://doi.org/10.54034/mic.e2235Keywords:
Acinetobacter baumannii, carbapenem resistance, intensive care unit, lower respiratory tractAbstract
Background: This study aims to determine alterations in the antibiotic resistance status of Acinetobacter baumannii strains isolated from lower respiratory tract samples of patients in intensive care units over the years. Methods: In this comprehensive study, A. baumannii strains isolated from aspirate and sputum samples of patients hospitalized in intensive care units of a second-stage state hospital between January 2018 and December 2022 were meticulously and retrospectively investigated and analyzed for antimicrobial resistance. Results: The rate of aspirate and sputum samples in the study was 18.1% (754/4151); The positivity rate of cultures was 51.7% (390/754); The rate of those associated with A. baumannii was found to be 65.6% (256/390).. 90.2% of the isolates were isolated from the general intensive care unit (231/256). The rates of A. baumannii isolated from aspirate and sputum samples were 67.4% (213/316) and 58.1% (43/74), respectively. The carbapenem resistance rate in A. baumannii isolates grown in aspirate samples was 96.5%, fluoroquinolone resistance was 91.7%; The carbapenem resistance rate in sputum samples was 96.1% and fluoroquinolone resistance was 90.9%. The most effective antibiotics against A. baumannii strains isolated from both aspirate and sputum samples were colistin 100% (n=256), TMP/SXT 55.8% (143/256), tigecycline 50.3% (129/256), respectively. Conclusion: Our study reveals a concerning trend-a high frequency of multidrug-resistant A. baumannii isolates are being identified in the Central Anatolia region of our country. This high prevalence, which is a cause for immediate concern, underscores the urgent and immediate need for robust infection control measures to curb the spread of A. baumannii in hospitals.
References
Esposito S and Leone S. Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int. J. Antimicrob. Agents 2007;29,494–500.
Baker S, Thomson N, Weill FX, Holt KE. Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens. Science New York N.Y. 2018; 360,733–8.
Temel A, Eraç B. A global threat: Acinetobacter baumannii infections, current condition in antimicrobial resistance and alternative treatment approaches. Turk Hij Den Biyol Derg, 2020; 77: 367-78
Arrigoni R, Ballini A, Santacroce L, Palese LL. The Dynamics of OXA-23 β-Lactamase from Acinetobacter baumannii. Int J Mol Sci. 2023;24(24):17527.
Agarwal S, Kakati B, Khanduri S and Gupta S. Emergence of carbapenem resistant non-fermenting gram-negative bacilli isolated in an ICU of a tertiary care hospital. Journal of clinical and diagnostic research: JCDR 2017;11(1),DC04.
Kousouli E, Zarkotou O, Polimeri K, Themeli-Digalaki K, Pournaras S. Impact of bloodstream infections caused by carbapenem-resistant gramnegative pathogens on ICU costs, mortality and length of stay. Infect Prev Pract 2019;1:100020.
Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob agents chemother 2018;62(1),10-1128.
Busani S, Serafini G, Mantovani E, Venturelli C, Giannella M, Viale P, et al. Mortality in patients with septic shock by multidrug resistant bacteria: risk factors and impact of sepsis treatments. J. Intensive Care Med. 2019;34, 48–54.
Chen YP, Liang CC, Chang R, Kuo CM, Hung CH, Liao TN, et al. Detection and colonization of multidrug resistant organisms in a regional teaching Hospital of Taiwan. Int. J. Environ. Res. Public Health 2019;16:1104.
Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. Clin. Infect. Dis. 2019;68, 873–84.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018;18, 318–27.
Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem resistant Acinetobacter baumannii: A challenge in the intensive care unit. Front. Microbiol. 2022;13, 1045206.
National Healthcare Safety Network, NHSN Organism List (All Organisms, Top Organisms, Common Commensals, MBI Organisms, and UTI Bacteria). Atlanta, 2018, [https://www,cdc,gov/nhsn/xls/2018- NHSN-Organisms-List-Validation,xlsx] (Accessed: 06.12.2023).
Vrancianu CO, Gheorghe I, Czobor IB, Chifriuc MC. Antibiotic resistance profles, molecular mechanisms and innovative treatment strategies of Acinetobacter baumannii. Microorganisms 2020;8(6):935. https://doi.org/10. 3390/microorganisms8060935
Lee CM, Kim CJ, Kim SE, Park HJ, Bae JY, Choi HJ, et al. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia. J Glob Antimicrob Resist 2022;31:45–51. https://doi.org/10.1016/j.jgar.2022. 08.010
Hafiz TA, Alghamdi SS., Mubaraki MA, Alghamdi SS, Alothaybi A, Aldawood E, et al. A two-year retrospective study of multidrug-resistant Acinetobacter baumannii respiratory infections in critically Ill patients: Clinical and microbiological findings. J Infect Public Health. 2023;16(3), 313-9.
European Centre for Disease Prevention and Control & World Health Organization. Regional Ofce for Europe. Antimicrobial resistance surveillance in Europe 2022–2020 data. (2022). World Health Organization. Regional Ofce for Europe. https://apps.who.int/iris/handle/10665/351141. License: CC BY-NC-SA 3.0 IGO
Whiteway C, Breine A, Philippe C, Van der Henst C. Acinetobacter baumannii. Trends Microbiol. 2022;30, 199–200.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008;21, 538–82.
Roca I, Espinal P, Vila-Farres X, Vila J. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front. Microbiol. 2012;3:148.
Greene C, Wu J, Rickard AH, Xi C. Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces. Lett. Appl. Microbiol. 2016b;63, 233–9.
Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS, Chopade BA. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol. 2011;62(3), 328-38.
Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The mechanisms of disease caused by Acinetobacter baumannii. Front. Microbiol. 2019;10:1601.
Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccine 2021;9(6):570.
Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin. Microbiol. Infect. 2019;25(8):951–957.
Weinberg SE, Villedieu A, Bagdasarian N, Karah N, Teare L, Elamin WF. Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches. Infect Prev Pract. 2020;2(3),100077.
Abed AB., Korcan SE, Güngör S. Antibiotics profile map of clinical A. baumannii strains isolated from health institutions in Turkey: a database search study and analysis of publications from 2011 to 2022. Bulletin of the National Research Centre, 2023;47(1), 15.
Giammanco A, Cala C, Fasciana T, Dowzicky MJ. Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. mSphere 2, 2017;e00310–e00316.
Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb genom. 2019;5(10). e000306.
Central Asian and Eastern European Surveillance of Antimicrobial Resistance Annual report 2017. WHO. 2017.
Dadgostar P. Antimicrobial resistance: implications and costs. Infect. Drug Resist. 2019;12, 3903–10.
Tiku V. Acinetobacter baumannii: Virulence strategies and host defense mechanisms. DNA and Cell Bio. 2022;41(1), 43-8.
Uğur M, Genç S. Three-Year Resistance Profile of Acinetobacter baumannii and Pseudomonas aeruginosa Strains Isolated from Intensive Care Units. Turk J Intensive Care 2019;17(3).130-7.
Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol. 2004;53(12):1233-40.
Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug. Resist. Updates. 2010;13(6):151-71.
Mantzarlis K, Makris D, Zakynthinos E. Risk factors for the first episode of Acinetobacter baumannii resistant to colistin infection and outcome in critically ill patients. J. Med. Microbiol. 2020;69(1)35–40.
Papathanakos G, Andrianopoulos I, Papathanasiou A, Priavali E, Koulenti D, Koulouras V. Colistin resistant Acinetobacter baumannii bacteremia: A serious threat for critically ill patients. Microorganisms. 2020;8(2),287.
Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microb. Pathog. 2020;139, 103887.
Cesur S, Irmak H, Yalçın AN, Berktaş M, Baysan BÖ, Kınıklı S, et al. Antibiotic susceptibilities of Acinetobacter baumannii strains isolated from various culture samples of patients in the intensive care unit. omj. 2017;9:51-5.
Novović K, Jovčić B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics. 2023;12(3), 516.
Š eputienė V, Povilonis J, Armalytė J, Suž iedėlis K, Pavilonis A ES. Tigecycline – how powerful is it in the fight against antibiotic-resistant bacteria? Medicina. 2010;46 (4), 240–8.
Chen CH, Wu PH, Lu MC, Ho MW, Hsueh PR. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat acinetobacter baumannii in the Asia-pacific region: results from the antimicrobial testing leadership and surveillance (ATLAS) program, 2020. I J Antimic Ag. 2023;61(2), 106707.
Nazlı Zeka A, Arda B, Sipahi OR, Uyar M. Factors associated with mortality in carbapenem-resistant Acinetobacter baumannii infections developing in intensive care: a prospective observation study. FLORA. 2020;25(3):391-400.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nazife Akman, Pelin Özmen, Mustafa Türk

This work is licensed under a Creative Commons Attribution 4.0 International License.